Dicot develops a new potency drug that aims to become the first choice globally for the treatment of erectile dysfunction and premature ejaculation.
In August 2023, Dicot started its clinical phase 1 study of the drug candidate LIB-01 with the primary objective of evaluating the safety profile in humans. Prior to this, Dicot has received approvals from both the Swedish Medical Products Agency and the Ethical Review Board. The first study participants were dosed in early September. Further development is intended to be carried out under own auspices up to and including clinical phase 2a and then together with major pharmaceutical companies to introduce LIB-01 to the world market.
Dicot's shares are listed on Spotlight Stock Market and the company has approximately 4,100 shareholders.